1. Home
  2. VYGR vs RNAC Comparison

VYGR vs RNAC Comparison

Compare VYGR & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Voyager Therapeutics Inc.

VYGR

Voyager Therapeutics Inc.

HOLD

Current Price

$3.74

Market Cap

194.0M

Sector

Health Care

ML Signal

HOLD

Logo Cartesian Therapeutics Inc.

RNAC

Cartesian Therapeutics Inc.

HOLD

Current Price

$6.61

Market Cap

214.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VYGR
RNAC
Founded
2013
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
194.0M
214.8M
IPO Year
2015
2016

Fundamental Metrics

Financial Performance
Metric
VYGR
RNAC
Price
$3.74
$6.61
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
6
Target Price
$21.00
$35.00
AVG Volume (30 Days)
862.4K
185.1K
Earning Date
03-09-2026
03-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$10,135,000.00
$2,797,000.00
Revenue This Year
$54.19
N/A
Revenue Next Year
$20.22
$26.02
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.65
$5.98
52 Week High
$5.55
$16.79

Technical Indicators

Market Signals
Indicator
VYGR
RNAC
Relative Strength Index (RSI) 42.89 42.39
Support Level $3.36 $6.44
Resistance Level $3.74 $8.10
Average True Range (ATR) 0.32 0.76
MACD -0.06 -0.15
Stochastic Oscillator 4.87 9.79

Price Performance

Historical Comparison
VYGR
RNAC

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

About RNAC Cartesian Therapeutics Inc.

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.

Share on Social Networks: